David R. Gandara
University of California Davis Medical Center(US)UC Davis Comprehensive Cancer CenterUniversity of California, Davis(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Ovarian cancer diagnosis and treatment, Cancer therapeutics and mechanisms, Peptidase Inhibition and Analysis, Multiple Myeloma Research and Treatments
Most-Cited Works
- → A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer(2009)286 cited
- → Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma(2004)114 cited
- → Trastuzumab plus Docetaxel in HER2/neu–Positive Non–Small-Cell Lung Cancer: A California Cancer Consortium Screening and Phase II Trial(2004)109 cited
- → GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.(1989)101 cited
- → The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial(2005)96 cited
- → A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study(2009)